Search strategy.

<div> Introduction Chronic kidney disease is a major public health concern among people living with human immunodeficiency virus (PLWHIV) who are taking tenofovir disoproxil fumarate-based regimen. Despite the available evidence showing a high prevalence of CKD in this population, comprehensive pooled estimate of CKD among PLWHIV receiving TDF based regimen across the globe is lacking. Hence, the present systematic review aimed to provide a global pooled prevalence estimate of CKD. Method We conducted a systematic review of literatures published between January 2000 and May 2024. Articles and grey literature were searched from the following databases and search engine: PubMed, EMBASE, Scopus, Web of science, The Cumulative Index to Nursing and Allied Health Literature (CINHAL), and Google Scholar. We included eligible studies that report magnitude of CKD in TDF based regimen. We executed the pooled CKD, subgroup analysis, and funnel plot using random effect model. All statistical analysis including sensitivity analysis were made using Stata 17 software. Results Sixty-nine studies with 88299 participants included in this meta-analysis. The pooled prevalence of CKD was 7% (95% CI:6–8). CD4 count less than 200 copies per milliliter, and being female were associated with CKD. Conclusion We concluded that the magnitude of CKD across the globe is high in people living with HIV who have received TDF based regimen. Early identification of CKD by considering regular renal function monitoring, and risk factors especially low CD4 count, and female gender at birth are essential. Trial registration The protocol has been prospectively registered with PROSPERO ((<a href="https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020136813" target="_blank">CRD42020136813</a>). </div>